Shi, Junwei

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 1,870

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation

Shi, J., Whyte, W. A., Zepeda-Mendoza, C. J., Milazzo, J. P., Shen, C., Roe, J.-S., Minder, J. L., Mercan, F., Wang, E., Eckersley-Maslin, M. A., et al. (2013) · Genes & Development

Chromatin Remodeling and CancerGenomics and Chromatin Dynamics

Cited by 463

Optimized base editors enable efficient editing in cells, organoids and mice

Zafra, M. P., Schatoff, E. M., Katti, A., Foronda, M., Breinig, M., Schweitzer, A. Y., Simon, A., Han, T., Goswami, S., Montgomery, E., et al. (2018) · Nature Biotechnology

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 347

Histone H2B ubiquitin ligase RNF20 is required for MLL -rearranged leukemia

Wang, E., Kawaoka, S., Yu, M., Shi, J., Ni, T., Yang, W., Zhu, J., Roeder, R. G., & Vakoc, C. R. (2013) · Proceedings of the National Academy of Sciences

Acute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

Cited by 121

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma

Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 106

The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer

Wang, E., Kawaoka, S., Roe, J.-S., Shi, J., Hohmann, A. F., Xu, Y., Bhagwat, A. S., Suzuki, Y., Kinney, J. B., & Vakoc, C. R. (2015) · eLife

Genomics and Chromatin DynamicsAcute Lymphoblastic Leukemia research

Cited by 54

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

Lu, S., Zhang, Q., Meng, X., Sun, Y., Xiong, H. H., Lv, D., Wang, X., Wu, L., Dong, X., Ji, Y., et al. (2024) · Journal of Clinical Oncology

Cancer therapeutics and mechanismsMonoclonal and Polyclonal Antibodies Research

Cited by 1